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1. Introduction
  
 In the end of 2019, a number of people in Wuhan, 
China, were reported to contract pneumonia-
like illnesses that in some of the infected ones 
immediately developed into acute respiratory 
distress syndrome (ARDS) (Huang et al. 2020). The 
disease, termed officially by WHO as coronavirus 
disease 2019 (COVID-19) in February 2020, was 
soon discovered to be linked with a novel infectious 
agent named as severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) (Dhama et al. 2020). At 
present, COVID-19 has been classified as a pandemic 
with more than 66 million positive cases worldwide 
(WHO 2020). With such devastating global profile, the 
emergence of COVID-19 and its suggested causative 
agent, SARS-CoV-2, has marked an ominous timeline 
in the history of human modern civilization. 
 Much has been done at the frontiers to demonstrate 
the perilous nature of SARS-CoV-2 and COVID-19, the 
disease it causes (Dhama et al. 2020; Harapan H et al. 
2020; Vabret et al. 2020). In parallel, collective global 
efforts to search for effective COVID-19 vaccines 
and clinically proven antiviral drugs to combat 
SARS-CoV-2 have increased our chance to provide 
safe and sound COVID-19 preventive measures and 
pharmacological treatments, respectively (Vabret et 
al. 2020; Corey et al. 2020; Guy et al. 2020). In addition 
to that, wide-concerted curated efforts to provide the 
best clinical guidelines for COVID-19 patients have 
been a remarkable step in response to the COVID-19 
pandemic (Tobaiqy et al. 2020; Sanders et al. 2020). 
However, even with those marvelous endeavors, 
much remains elusive in terms of our understanding 
whether currently given drugs can help SARS-CoV-2 
infected patients to clear off the viral particles and 
promote successful recovery from infection. 
 A further important pharmacological aspect 
to consider is the occurrence of inflammatory 
responses in COVID-19 patients that might result in 
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the repression of biological activities of some drug-
metabolizing enzymes (DMEs) and transporters 
(Aitken AE et al. 2006; Vabret et al. 2020). The 
inflammation process might result in a transient 
phenoconversion phenomenon in which there is 
a deviation between the function encoded in the 
genotype and the phenotype expression to some 
extent (Shah and Smith 2015). This inflammation-
mediated phenoconversion is particularly important 
with COVID-19 patients who have comorbidities. 
These patients might have multiple drug therapies 
needed to be metabolized and transported by DMEs 
and transporters which are potentially impacted by 
inflammation-mediated phenoconversion. In this 
review, we attempt to discuss the mechanisms of how 
SARS-CoV-2 can promote inflammatory responses 
in the infected patients and how such events will 
potentially result in the emergence of inflammation-
mediated phenoconversion. In the end, we will address 
the possible implications of such phenoconversion 
events in the management of COVID-19 patients, 
which further shall provide safer and scientifically 
sound pharmacological interventions.
2. COVID-19 and Inflammation
 Accumulating evidence has suggested that SARS-
CoV-2 enters the host cells via ACE2-mediated 
endocytosis and carry out their replication in the 
cytoplasm of the infected cells (Hoffmann et al. 2020). 
After assembling all components required for their 
replication, the newly produced SARS-CoV-2 particles 
further relocate into the extracellular space, ready to 
infect new host cells (Hoffmann et al. 2020; Tang et 
al. 2020). Just after entering the cells, the presence 
of SARS-CoV-2 genome in the endosome and/or 
cytoplasm has been suggested to trigger the activation 
of innate intrinsic antiviral response in the host cells 
(Vabret  et al. 2020; Tang et al. 2020; Li et al. 2020). 
Several RNA sensors, for example Toll-like receptors 
7 and 8 in the endosome and MDA-5 and RIG-I in the 
cytoplasm, are capable to detect RNA viral genome, 
including SARS-CoV-2 genome, and the activation 
of these sensors subsequently initiates a series of 
cascade reactions to stimulate the secretion of pro-
inflammatory cytokines that leads to the recruitment 
of immune cells to the sites of infection (Vabret et al. 
2020; Tang et al. 2020; Li et al. 2020). 
 In general, the release of pro-inflammatory 
cytokines into the extracellular regions of infection 
sites serves as a good indicator for host immune 
activation upon introduction of foreign particles and 
pathogens, such as bacteria or viruses, into the host 
body (Chaplin 2010; Rouse and Sehrawat 2010). In 
the context of SARS-CoV-2 infection, inflammatory 
reactions at the sites of infection, including lungs, 
have been suggested as the results of host innate 
recognition to certain components of SARS-CoV-2 
particles and/or countermeasure responses to robust 
yet unidentified viral activities in the cytoplasm of 
the infected cells (Vabret et al. 2020; Li  et al. 2020; 
Vardhana and Wolchok 2020; Tay et al. 2020). 
 Inflammation is an important response to fend off 
the invading pathogens (Chaplin 2010; Rouse  and 
Sehrawat 2010). However, it is worth to note that in 
some cases, a dysregulated inflammatory response 
posits a serious threat for host cells (Rouse  and 
Sehrawat 2010). Indeed, recent evidence showed that 
COVID-19 patients, particularly the ones with severe 
status, experienced hyper-inflammatory responses 
that have been suggested to lead to multiorgans 
failure (Huang et al. 2020; Chen et al. 2020). Early 
reports indicate that inflammation was initiated at 
the respiratory tracts of the COVID-19 patients and 
in the severe COVID-19 patients, it soon developed 
as acute respiratory distress syndrome (Chen et al. 
2020). Pathogenic mechanisms on how SARS-CoV-2 
causes such fatal syndrome remain largely unknown. 
However, scientists expect it might be similar to that 
of SARS-CoV (Vabret et al. 2020; Tay et al. 2020).
 Coronavirus replication is likely to activate the 
host cells defense system that leads to the increased 
production of antiviral proteins such as interferon 
and the subsequent release of different types of 
pro-inflammatory cytokines (Fung and Liu 2019; 
Li et al. 2020). In the context of COVID-19, levels of 
pro-inflammatory cytokines, such as interleukins 
(IL-2, IL-6, IL-7, IL-8, IL-10), tumor necrosis factor 
(TNF)-α, granulocyte colony-stimulating factor 
(GCSF), interferon gamma-induced protein (IP)-10, 
monocyte chemoattractant protein (MCP)-1, and 
macrophage inflammatory protein (MIP)-1α, were 
reported to increase, especially in ICU (intensive 
care unit) patients with severe COVID-19, suggesting 
the possible correlation between increased pro-
inflammatory cytokine levels and COVID-19 severity 
(Huang et al. 2020; Vabret et al. 2020; Tang et al. 2020; 
Vardhana and Wolchok 2020; Chen et al. 2020). 
 Immediate release of pro-inflammatory cytokines 
can occur due to insults from certain stressors and 
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may include AngII-associated lung injury, as observed 
in the SARS-CoV infection (Kuba et al. 2005; Imai et 
al. 2008). AngII-mediated inflammation accompanied 
by increased vascular permeability, lung edema, and 
enhanced penetration of neutrophils to the sites of 
infection due to the reduced expression of ACE2 have 
been demonstrated in the acute respiratory disease 
(ARD) murine model (Imai et al. 2005).
 In severe COVID-19 patients, the occurrence 
of hyper-inflammation as a result of cytokine 
storm has been suggested (Vabret et al. 2020; 
Vardhana and Wolchok 2020; Tay et al. 2020). 
Cytokine storm is a condition where excessive pro-
inflammatory cytokines, for example interleukin(s) 
and chemokine(s), are produced by the host immune 
cells in response to foreign insult(s), including 
in the event of betacoronavirus infection such as 
SARS-CoV8, MERS-CoV, and possibly SARS-CoV-2 
(Tisoncik et al. 2012; Channappanavar and Perlman 
2017; Song et al. 2020). Indeed, as a hallmark of 
severe MERS-CoV infection and to some extent, 
SARS-CoV-2 infection, elevated levels of certain pro-
inflammatory cytokines, for example IL-6, in the late 
event of infection have been specifically suggested to 
correlate with respiratory failure, ARDS, and adverse 
clinical outcomes (Vabret et al. 2020; Tay et al. 2020; 
Channappanavar and Perlman 2017; Song et al. 2020). 
With this in mind, proper induction of inflammation 
as an antiviral response and subsequent resolution 
at a given time to limit the immunopathology of 
inflammatory reactions on the infected patients shall 
hold critical roles in effort to obtain a better clinical 
outcome.
 
3. Inflammation-Mediated Phenoconversion: 
Evidence and Mechanisms
 
Mounting non-clinical and clinical evidence 
have shown that elevated production of some pro-
inflammatory cytokines (such as IL-1, IL-6, IFN or, 
TNF) during the inflammation process potentially 
alters the genetic modulation of some DMEs, reduces 
their hepatic levels, and therefore, decreases their 
metabolic activities (Aitken et al. 2006; Shah and 
Smith 2015; Storelli et al. 2018). This condition might 
lead to a transient phenoconversion of DMEs, which 
is defined as a discordance between their genotypic 
status (normal metabolizer/NM) and their phenotypic 
expression (intermediate metabolizer/IM or poor 
metabolizer/PM). It was estimated that the metabolic 
conditions, including the untimely death of virus-
infected cells in the absence of swift elimination by 
phagocytic cells (Rock and Kono 2008; Nainu et al. 
2017). In addition to the mechanism described above, 
the extracellular presence of SARS-CoV-2-related pro-
inflammatory cytokines is triggered by the occurrence 
of pyroptosis in the macrophages and lymphocytes of 
COVID-19 patients (Yang 2020). Leakage of danger-
associated molecular patterns (DAMPs) and/or 
pathogen-associated molecular patterns (PAMPs) 
from virus-infected cells that undergo pyroptosis, a 
type of inflammation-related cell death, is a potential 
way to induce rapid expression of pro-inflammatory 
cytokines (Bergsbaken et al. 2009; Zhao and Zhao 
2020). The formation of NLRP3 (NOD-like receptor 
protein 3) inflammasome and the rapid secretion 
of IL-1β in macrophages have been demonstrated 
in SARS-CoV infection (Chen  et al. 2019). While a 
similar mechanism is subject for demonstration 
in SARS-CoV-2 infection, the formation of NLRP3 
inflammasome has been shown to result in the vast 
induction of pro-inflammatory cytokines (Bergsbaken 
et al. 2009). Inflammation is a complex process that 
can occur via multiple distinct pathways (Chen et al. 
2017). In addition to possible immune activation by 
innate and adaptive recognition to SARS-CoV-2 and 
the outcome of pyroptotic cell death, inflammatory 
responses might be induced via the Angiotensin-
ACE2-mediated axis (Bergsbaken et al. 2009; Vabret 
et al. 2020; Yang 2020). Early reports have suggested 
that SARS-CoV-2 infects human host cells through 
ACE2-mediated and TMPRSS2-supported endocytosis 
(Hoffmann et al. 2020) (Vabret et al. 2020; Yang 2020). 
This entry mechanism is similar to that of SARS-
CoV that eventually leads to the downregulation of 
ACE2 expression in the infected cells (Li et al. 2003; 
Wang et al. 2008; Glowacka et al. 2010). Considering 
that SARS-CoV-2 has been shown to infect host 
cells through a similar ACE2-dependent viral entry 
mechanism, it is possible that a similar negative 
regulation of ACE2 gene expression might occur in the 
infected host cells. Physiologically, ACE2 plays a vital 
role in the degradation of Angiotensin II (AngII) into 
vasoprotective Ang1-7 and Ang 1-9 molecules (Tikellis 
and Thomas 2012). Reduced expression of pulmonary 
ACE2 has been reported to result in the increased 
induction of AngII-mediated inflammation leads to 
the emergence of fibrosis and lung injury (Imai et al. 
2005; Imai et al. 2008; Kuba et al. 2005). Therefore, 
pathophysiological phenotype for COVID-19 patients 
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reported to have a prolonged half-life of theophylline, 
which was assumed to be due to a decrease in the 
catalytic activity of the drug-metabolizing enzyme 
(Chang et al. 1978). Shedlofsky et al. 1994 confirmed 
the hypothesis by doing an experiment in which they 
injected lipopolysaccharide (LPS) to healthy male 
volunteers to induce acute inflammation, who were 
then administered with theophylline (Shedlofsky et 
al. 1994). As expected, LPC induced the increased of 
TNFΑ, IL-1ß, and IL-6 blood levels and caused a 22% 
decrease in theophylline clearance (Shedlofsky et al. 
1994).
Another clinical example of the effects of 
inflammation-mediated reduction of CYP metabolic 
capacity can be observed in sepsis children treated 
with antipyrine (Carcillo et al. 2003). It was found that 
there was at least two times a reduction of antipyrine 
metabolic clearance in patients with sepsis compared 
to the healthy control group (Carcillo et al. 2003). 
The substantial trend of reduction was negatively 
correlated with the amount of IL-6 as well as the 
level of nitric oxide (NO) production in the blood 
(Carcillo et al. 2003). Antypirine is metabolized by 
several CYP sub-families such as CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2C18, and CYP3A4 (Engel et al. 
1996). Therefore, there was a possibility that elevated 
levels of cytokines during inflammation as well as 
the increase of NO levels may suppress the catalytic 
activities of those CYP enzymes.
A next clinical example was reported in rheumatoid 
arthritis (RA) patients who used simvastatin (a CYP3A4 
subsrate) (Lee et al. 2017). It was reported that during 
simvastatin treatment, RA patients had a significant 
increase of simvastatin area under curve (AUC) [84.3 
ng.h/ml (SD = 53.6)] compared to the reference value 
reported in healthy individuals (17–50 ± 10–22 ng․h/
ml) (Lee et al. 2017). RA patients commonly have an 
elevated circulating IL-6, and therefore potentially 
have a depressed CYP3A4 metabolic activity due to 
IL-6 actions. Interestingly, the co-administration of 
sarilumab (a human monoclonal antibody which 
works by blocking IL-6Rα) could return the AUC of 
simvastatin to the normal concentration [47.9 ng.h/ml 
(SD = 33.4)] (Lee et al. 2017). It indicated that IL-6 plays 
an important role in depressing the activity of CYP3A4 
and the transient decrease of CYP3A4 metabolic 
activity could be normalized by IL-6 inhibitor 
administration. It was estimated that inflammation 
might reduce the CYP3A4 metabolic activity by 20 to 
60% (Haas et al. 2003). An equivalent scenario was 
clearance of some drugs was reduced substantially by 
20 to 70% in inflammation state (Aitken et al. 2006). 
It seems that although the genotype status of the 
responsible DMEs corresponds to normal metabolic 
function, their phenotypic expressions might 
differ during inflammatory conditions. Therefore, 
phenoconversion of DMEs might potentially impact 
the drug efficacy and safety if it is not well recognized 
and managed clinically. 
In vitro experiments by incubation of pro-
inflammatory cytokines with rodents and human 
hepatocytes cultures showed that the cytokines 
were able to downregulate some cytochrome 
P450 (CYP450) biosynthesis (Sunman et al. 2004; 
Aitken et al. 2006; Shah and Smith 2015). Likewise, 
experimental inflammatory or infection models 
which were developed by inoculation of bacterial, 
viral, parasitic, or other inflammatory inducers (such 
as cytokines, interferons, irritants, or adjuvants) 
indicated that increased exposure to inflammatory 
cytokines led to the decrease of the total amount 
of hepatic CYP450 (CYP) expressions and their 
metabolic activities were markedly reduced (Sewer 
et al. 1997; Siewert et al. 2000; Aitken et al. 2006; 
Shah and Smith 2015). The reduction rate of mRNA 
expression of some CYP isoenzymes was in line with 
the increase in the production of pro-inflammatory 
cytokines. Comprehensive reviews on the in vitro and 
in vivo studies on the inflammation-mediated CYP 
depression can be read elsewhere (Aitken et al. 2006; 
Morgan et al. 2011; Shah and Smith 2015).
In terms of clinical studies, the first notable case 
on the clinical impact of inflammation on drug 
biotransformation was observed during the influenza 
B epidemic in Washington, US, in 1980 (Kraemer et 
al. 1982). Eleven young asthmatic patients who used 
theophylline routinely as a maintenance treatment 
developed theophylline related toxicities, such as 
convulsions, gastrointestinal disturbances, and 
headache, because of the elevated blood concentration 
of theophylline (Kraemer et al. 1982). Alteration of 
metabolic clearance of theophylline was assumed 
as the culprit (Kraemer et al. 1982). Theophylline 
is extensively metabolized by CYP1A2 enzyme in 
the liver and therefore, influenza B infection was 
considered to decrease the metabolic activity of 
the enzyme. The comparable condition was found 
previously in patients treated with theophylline who 
were infected with influenza A (Chang et al. 1978). 
Patients with viral upper respiratory infection were 
also reported in the interaction between sirukumab 
(another human IL-6 blocker monoclonal antibody) 
with several CYP substrates such as midazolam (a 
CYP3A substrate), omeprazole (a CYP2C19 substrate), 
and warfarin (a CYP2C9 substrate) in RA patients 
(Zhuang et al. 2015). The high systemic level of IL-6 
in RA condition seemed to downregulate the CYP 
enzymes, resulting in the higher blood concentration 
of midazolam, omeprazole, and warfarin than in 
normal persons (Zhuang et al. 2015). However, after 
a single administration of sirukumab, there was a 
decrease in the level of midazolam, omeprazole, 
and warfarin exposures by 30-35%, 37-45%, and 18-
19%, respectively, to the level of exposures in the 
normal condition (Zhuang et al. 2015). The results 
were aligned with the idea that IL-6 has an ability 
to transiently suppress metabolic activities of some 
CYP sub-families which can be conversed by an IL-6 
blocker.
Another important CYP subtype that is potentially 
depressed by cytokines is CYP2D6. It was reported that 
CYP2D6 catalytic activity was decreased by about 90% 
in persons with HIV compared to the normal control 
(Jones et al. 2010). It was also noted that about 25% of 
patients experienced phenoconversion in which they 
were genetically NM but phenotypically PM (Jones 
AE et al. 2010). The CYP2D6 activity was inversely 
correlated with the blood concentration of TNFα (Jones 
AE et al. 2010). Interestingly, from the same study, it 
was also found that the activity of N-acetyltransferase 
2 (NAT2), a phase II drug metabolizing enzyme, 
was also lessened by 53% compared to the healthy 
individuals and results in a significant phenotypic 
conversion from fast to slow acetylation (Jones AE et 
al. 2010). The rate of phenoconversion is associated 
with the progression of HIV disease (Jones AE et al. 
2010; Shah and Smith 2015). However, the overall 
impact of inflammation on metabolic capacities of 
Phase II drug metabolizing enzymes generally has 
not been comprehensively explored yet (Aitken et al. 
2006).
The molecular mechanisms of inflammation-
mediated phenoconversion are still not well elucidated. 
However, there have been some mechanisms 
proposed to explain how the pro-inflammatory 
cytokines might suppress the amount and catalytic 
functions of CYP enzymes. Firstly, the release of pro-
inflammatory cytokines might alter the regulation 
of some particular transcription factors, such as 
pregnane X receptor (PXR), constitutive androstane 
receptor (CAR), retinoid X receptor (RXR), hepatocyte 
nuclear factor (HNF), nuclear factor-κB (NF-κB), and 
CCAAT/enhancer-binding protein beta (C/EBPβ), in the 
liver (Aitken et al. 2006; Morgan et al. 2011). These 
modifications might lead to a repression of some 
CYP450 genes transcription, reducing the particular 
CYP mRNA levels and resulting in the decrease 
of respective CYP metabolic activities. Secondly, 
the chronic generation of the pro-inflammatory 
cytokines might induce nitric oxide synthase 2 
(NOS2) to produce hepatic NO (Aitken et al. 2006). 
NO was reported to potentially down-regulate the 
expression of CYP genes because it has a capability in 
modulating HNF4 and NFκB through the formation of 
S-nitrosylation (cysteine-nitrosylation) on the DNA-
binding domains of the transcription factors (Aitken 
et al. 2006; Morgan et al. 2011). Additionally, NO was 
also indicated to be able to decrease the metabolic 
activity of hepatic CYP enzymes by nitrosylation 
of cysteine or tyrosine residues in the various CYP 
structure (Aitken et al. 2006; Morgan et al. 2011).
Furthermore, inflammation was also reported to 
influence the function of main drug transporter such 
as P-glycoprotein (P-gp) transporter by suppressing 
its mRNA expression as well as its biological activity 
(Aitken et al. 2006; Morgan et al. 2011). In vivo models 
of acute inflammatory conditions, which were 
created by administration of chemical (turpentine 
oil) and biological (endotoxin) substances to induce 
the release of inflammatory cytokines, indicated the 
substantial decrease in the amount of Mdr1 (Abcb1) 
gene expression in the liver (gene responsible for 
encoding P-gp transporter) (Piquette-Miller et al. 
1998; Hartmann et al. 2005; Aitken et al. 2006; 
Morgan et al. 2011). Hartmann et al. 2005 reported 
a reduction in the systemic clearance of doxorubicin 
(a P-gp substrate), which led to a significant increase 
in the AUC of doxorubicin in the LPS-induced 
acute inflammatory model (Hartmann et al. 2005). 
Doxorubicin is cleared primarily via biliary secretion 
which is facilitated by P-gp transporter. Therefore, the 
reduction of hepatic P-gp level due to inflammation 
can decrease its clearance from the blood.
It was estimated that there was about 50% to 
70% reduction of hepatic expression and activity of 
the drug transporter within one or two days after 
a chemical irritant injection (Piquette-Miller et al. 
1998). The alteration was seemingly produced by a 
repression of Mdr1a and Mdr1b (isoforms of Mdr1 in 
mice) nuclear gene transcription via modulation of 
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PXR and CAR expression (Sukhai et al. 2000; Morgan 
et al. 2011). From the in vitro and in vivo studies, Il-6 
and IL-1ß have been identified as the main actors 
in this cytokines-mediated downregulation of P-gp 
transporter (Morgan et al. 2011). Alteration of the P-gp 
transporter might produce a substantial change in the 
blood concentration of P-gp substrates.
4. Potential Clinical Implication of 
Inflammation-Mediated Phenoconversion in 
COVID-19
 As mentioned above, inflammation might reduce 
metabolic activities of a wide range of important CYP 
enzymes such as CYP1A2, CYP2B6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP2C18, and CYP3A4. Altogether, 
these CYP enzymes metabolize about 90% of drugs 
used in clinical settings (Zanger and Schwab 2013). 
Additionally, inflammation is also reported to influence 
the activities of Phase II drug metabolizing enzymes 
as well as P-gp drug transporter (Aitken et al. 2006; 
Morgan et al. 2011). Therefore, pharmacokinetics 
of drugs used by COVID-19 patients have a high 
probability to be altered by inflammation-mediated 
phenoconversion to some extent.
 Patients with COVID-19 experiencing severe 
conditions because of cytokine storms, are not 
uncommon to have comorbidities (Guan et al. 2020; 
Richardson et al. 2020). Several frequent diseases 
observed among COVID-19 patients are hypertension, 
coronary artery disease, obesity, diabetes, and chronic 
respiratory diseases (asthma, COPD) (Guan et al. 
2020; Richardson et al. 2020). Consequently, these 
particular patients might consume several drugs 
concomitantly. In table 1, we provide some lists of 
drugs which are theoretically used by COVID-19 
patients and their clinical impacts are potentially 
altered by inflammation-mediated phenoconversion. 
If COVID-19 patients are prescribed with normal 
doses of drugs intended to treat their co-existing 
comorbidities, their phenoconversion condition 
might potentially alter the clinical impacts of the 
drugs either by increasing the risk of side effects 
because of the elevated plasma concentrations of the 
drugs or inducing ineffectiveness in case of pro-drugs. 
 There are some conditions which are theoretically 
prone to be clinically affected by inflammation-
mediated phenoconversion such as: 1) elderly 
patients which normally experience physiological-
related changes such as decreased kidney and hepatic 
functions; 2) patients with pre-existing renal and liver 
diseases; 3) inflammation-mediated phenoconversion 
affecting not only the main metabolic pathway of the 
drug but also its alternative metabolic pathway; 4) 
decreased function of metabolic pathways because 
of genetic polymorphisms; 5) concomitant use of a 
drug which is an inhibitor of the DME or transporter; 
6) patients using a drug with a narrow therapeutic 
index. It is therefore important for clinicians to be able 
to identify patients who are sensitive to be affected 
by inflammation-mediated phenoconversion as well 
as to identify potentially affected drugs. It is also 
prudent that the clinical practitioners are being aware 
of the potential impact of inflammation-mediated 
phenoconversion and therefore could do a close 
monitoring to the potential side effects of particular 
drugs and if needed, to adjust the dose of the drugs.
 Yet, the impact of inflammation-mediated 
phenoconversion is probably hard to observe clinically 
since most drugs do have a wide therapeutic index 
and are commonly metabolized by several metabolic 
pathways. It has been reported that the failure of 
one metabolic pathway could be compensated by 
an alternative metabolic pathway (Bahar et al. 2017). 
Moreover, the presence of observable impact of side 
effects due to the increase of drug concentrations 
might also be shadowed by the COVID-19 symptoms 
or attributed to the COVID-19 infection.
 Another challenge to tackle the potential hazard 
of inflammation-mediated phenoconversion is the 
lack of guideline to manage this particular drug-
disease interaction. The current guidelines of drug 
interactions have not considered the importance 
of inflammation-mediated phenoconversion on 
drug safety yet. It is understandable since clinical 
studies regarding the topic is still limited and hard 
to translate to clinically actionable medication 
management. Yet, Van Tongeren et al. (2020) have 
recently published a standardized guideline to help 
the translation of the available clinical information of 
drug-disease interactions to applicable clinical action 
(Van Tongeren et al. 2020).
 Nevertheless, exploration of the clinical relevance 
of inflammation-mediated phenoconversion 
should still be further pursued. Since patients 
with comorbidities are commonly not included in 
randomized clinical trials, the evidence regarding 
the potential impact of drug-disease interactions is 
often lacking (Van Tongeren et al. 2020). Therefore, 
we need an alternative method that can be used 
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to predict the clinical impact of inflammation on 
drug pharmacokinetics. One method that could be 
employed is a physiologically based pharmacokinetic 
(PBPK) modeling (Jones and Rowland‐Yeo 2013). The 
quantitative biosimulation method can incorporate 
complex data which are predicted to affect drug 
pharmacokinetics such as drug-specific parameters 
as well as variability in internal and external 
characteristics of the individual patient (Jones and 
Rowland‐Yeo 2013; Vieira et al. 2014). The model has 
been successfully utilized to predict the magnitude 
of complex drug interactions (Storelli et al. 2019).
Table 1. List of drugs which are theoretically used by COVID-19 patients with comorbidities and potentially affected by 




















































































































Hypertension Coronary Artery disease Chronic respiratory 
diseases (asthma, COPD)
Potentially affected drugs 
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 Finally, the potential impact of inflammation 
on drug therapy during COVID-19 should be 
considered concomitantly with other intrinsic (such 
as genetics, comorbidity: renal disease or liver 
problems, physiological factors: age, gender and 
BMI) and extrinsic factors (such as herbal medicine, 
vitamins and dietary supplement, co-administered 
drug, and lifestyles: cigarette smoking, exercising, 
drinking alcohol) which might modify the safety 
and effectiveness of the drug. The co-existence of 
internal (genetic polymorphisms, comorbidity) and 
external (co-medication) factors may produce a 
complex interaction such as drug-drug-gene-disease 
interactions/DDGDIs (the overlapping condition of 
drug-drug-interaction, genetic polymorphisms, and 
disease) (Storelli et al. 2018). The DDGIs, which may 
produce a wider range of inter-individual variability 
on drug exposures than drug-drug interactions and 
drug-gene interactions, were observed in clinical 
practice (Storelli et al. 2018). Therefore, a clinical 
decision support system, which is commonly 
used to help healthcare professionals in managing 
drug interactions, should be created to be able to 
accommodate and process all the clinically relevant 
information in order to generate a personalized clinical 
practice to manage potential drug-related problems 
based on specific risk factors found in patients (Bahar 
2020).
5. Conclusion
 COVID-19 patients are often accompanied with 
chronic inflammation, a condition which might 
influence the pharmacokinetics of some drugs 
prescribed for them via alteration of drug metabolizing 
enzymes and transporters. Therefore, it is prudent 
that clinicians (prescribing doctors and pharmacists) 
should be aware on this drug-disease interaction to 
minimize the potential harm since inflammation-
mediated phenoconversion might become an 
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